-transparent.png){kind=logo}
Thirty-six patients with advanced carcinoma of the cervix received PALA at a dosage of 5 gm/m2 every three weeks. Thirty-three patients had received prior irradiation therapy and chemotherapy. No complete or partial responses were seen. The major toxicity was dermatologic and occurred in 16/36 (44%) of patients. Three patients experienced dose limiting disorientation or confusion. PALA was not associated with any antitumor activity in patients with advanced carcinoma of the cervix who had received prior chemotherapy. The results of this study indicate that PALA has no substantial activity in patients with advanced squamous carcinoma of the cervix who have previously received chemotherapy.
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
October 1989,
American journal of clinical oncology,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
April 1994,
American journal of clinical oncology,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
October 1995,
American journal of clinical oncology,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
August 1987,
American journal of clinical oncology,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
August 1986,
American journal of clinical oncology,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
April 1996,
American journal of clinical oncology,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
February 1991,
Investigational new drugs,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
January 1986,
Investigational new drugs,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
January 1986,
Investigational new drugs,
H B Muss, and
B Bundy, and
P J DiSaia, and
F B Stehman, and
J Beecham
December 1995,
American journal of clinical oncology,
